| Oct'19 | Jul'19 | Oct'18 | Jul'18 | |||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Revenues from contract with customer | ||||||
0 | 0 | 0 | 0 | |||
Expenses: | ||||||
Cost of revenue (excluding depreciation and amortization) | ||||||
0 | 0 | 0 | 0 | |||
Payment processing expense | ||||||
0 | 0 | 0 | 0 | |||
Sales and marketing | ||||||
0 | 0 | 0 | 0 | |||
Research and development | ||||||
0 | 0 | 0 | 0 | |||
General and administrative | ||||||
0 | 0 | 0 | 0 | |||
Depreciation | ||||||
0 | 0 | 0 | 0 | |||
Amortization | ||||||
0 | 0 | 0 | 0 | |||
Total expenses | ||||||
0 | 0 | 0 | 0 | |||
Operating loss | ||||||
0 | 0 | 0 | 0 | |||
Other income (expense) | ||||||
0 | 0 | 0 | 0 | |||
Change in fair value of warrant liability | ||||||
0 | 0 | 0 | 0 | |||
Interest income (expense) | ||||||
0 | 0 | 0 | 0 | |||
Total other income (expense) | ||||||
0 | 0 | 0 | 0 | |||
Loss before benefit from (provision for) income taxes | ||||||
0 | 0 | 0 | 0 | |||
Benefit from (provision for) income taxes | ||||||
0 | 0 | 0 | 0 | |||
Net loss | ||||||
0 | 0 | 0 | 0 | |||
Preferred stock dividends paid | ||||||
0 | 0 | 0 | 0 | |||
Accretion of redeemable preferred stock | ||||||
0 | 0 | 0 | 0 | |||
Net loss attributable to common stockholders, basic and diluted | ||||||
0 | 0 | 0 | 0 | |||
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) | ||||||
-0.07 | -10.42 | -7.02 | -6.66 | |||
Weighted-average common shares outstanding, basic and diluted (in shares) | ||||||
35,790,951 | 6,793,363 | 1,909,858 | 1,776,559 | |||
Subscription And Related Services [Member] | ||||||
Revenues | ||||||
0 | 0 | 0 | 0 | |||
Payment processing fees | ||||||
Revenues from contract with customer | ||||||
0 | 0 | 0 | 0 | |||
Life sciences | ||||||
Revenues from contract with customer | ||||||
0 | 0 | 0 | 0 | |||